Clinical trials: Necrotizing Pancreatitis
Pancreas Necrosis
Imaging Modalities for Pancreatic Collections
The purpose of this project is to provide appropriate administrative and technical supports for the warehousing and use of imaging data in pancreatic necrosis data for research purposes.
- Trial name
- NCT03556501
- Testing
- Endoscopy
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Acute Pancreatic Necrosis, Acute Pancreatitis (AP)
Serum TAM Receptor Tyrosine Kinase Ligands in Acute Pancreatitis
AXL and MERTK are homologous members of the TAM (TYRO3, AXL, MERTK) receptor tyrosine kinase family. They function as critical regulators of antiviral immunity, autoimmune responses, and tumor microenvironment modulation through…
- Trial name
- NCT07023055
- Where
- China
- Volunteers
- 896 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Severe Acute Pancreatitis
Relationship Between Acute Severe Pancreatitis and Mitochondrial DNA
Plasma mtDNA analysis aids in predicting pancreatic necrosis in severe acute pancreatitis patients.After the onset of severe acute pancreatitis, pancreatic necrosis and the content of mtDNA in plasma will increase, showing a…
- Trial name
- NCT04079777
- Testing
- Clinical treatment
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- First People's Hospital of Chenzhou
Necrotizing Pancreatitis
Molecular Analysis of Microbial DNA in Infected Necrotizing Pancreatitis
Necrotizing pancreatitis is a severe form of inflammation of the pancreas with subsequent destruction of the pancreas (necrosis).
- Trial name
- NCT01815489
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Pancreatitis, Acute Necrotizing
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults
GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level throughout the treatment period.
- Trial name
- NCT03245619
- Testing
- GSK3335065
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline